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Dientamoeba fragilis is a pathogenic protozoan parasite that is implicated as a cause of 28 
human diarrhea. A case-controlled study was conducted to determine the clinical signs 29 
associated with D. fragilis infection in children presenting to a Sydney Hospital. Treatment 30 
options are also discussed. Stool specimens were collected from children aged 15 years or 31 
younger and analysed for the presence of D. fragilis. A total of 41 children were included in 32 
the study along with a control group. Laboratory diagnosis was performed by microscopy of 33 
permanently stained fixed faecal smears and by real-time PCR. Gastrointestinal symptoms 34 
were present in 40/41 (98%) of these children with dientamoebiasis, with diarrhea (71%) and 35 
abdominal pain (29%) the most common clinical signs. Chronic gastrointestinal symptoms 36 
were present in 2% of cases. The most common antimicrobial used for treatment was 37 
metronidazole (n=41), with complete resolution of symptoms and clearance of parasite 38 
occurring in 85% of cases. A treatment failure rate occurred in 15% of those treated with 39 
metronidazole. Follow-up treatment comprising of an additional course of metronidazole or 40 
iodoquinol was needed in order to achieve complete resolution of infection and symptoms in 41 
this group. This study demonstrates the pathogenic potential of D. fragilis in children and as 42 
such it is recommended that all laboratories must routinely test for this organism and treat if 43 
detected.  44 
 45 











Dientamoeba fragilis is a trichomonad-like protozoan parasite with a worldwide distribution 54 
commonly found in the gastrointestinal tract of humans (Stark et al. 2006; Cepicka et al. 55 
2010; Stark et al. 2010a,b; Barratt et al. 2011a). Despite widespread belief to the contrary, 56 
numerous reports document that D. fragilis is a common cause of gastrointestinal disease in 57 
both developed and developing regions of the world and has the propensity to exist as a 58 
chronic infection with associated clinical signs of disease (Grendon et al. 1991; Grendon et 59 
al. 1995; Dickinson et al. 2002; Norberg et al. 2003; Stark et al. 2006; Stark et al. 2010b; 60 
Barratt et al. 2011a). It is found in all patient groups studied so far including the general 61 
population, travellers and HIV infected individuals (Stark et al. 2005; Stark et al. 2007a; 62 
Stark et al. 2007b; Barratt et al. 2011a). 63 
 Several studies have reported that children are susceptible to infection with D. fragilis 64 
and present with clinical symptoms at higher rates than adults (Preiss et al. 1991; Ayadi & 65 
Bahri, 1999; Crotti et al. 2005). Consequently, D. fragilis should be considered in the 66 
differential diagnosis of gastrointestinal infections in children (Spencer et al. 1979; Keystone 67 
et al. 1984; Preiss et al. 1990; Stark et al. 2009) but it is generally ignored as a cause of 68 
disease. Clinical symptoms reported include acute and chronic diarrhea, lower abdominal 69 
pain, nausea, flatulence and constipation ( Spencer et al. 1983; Cuffari et al. 1998). 70 
Transmission of D. fragilis is believed to be via the fecal-oral route, but the mechanism and 71 
whether it includes a helminth or a cyst-like stage, are still unclear (Stark et al. 2006; Barratt 72 
et al. 2011b). 73 
 Here we review existing knowledge on dientamoebiasis in children. A case-controlled 74 
study was also conducted to document the extent of D. fragilis infections in children 75 






MATERIALS AND METHODS   79 
                      80 
The study was performed at St. Vincent’s Hospital, Sydney. Laboratory and clinical records 81 
of D. fragilis infected children were collected from August 2004 to July 2010. The following 82 
criteria were used for inclusion into this study: children were aged 15 years or less, full 83 
clinical history, confirmed laboratory diagnosis of D. fragilis as the sole pathogen, treatment 84 
history, follow up stool samples were analysed to evaluate treatment regimes, clinical follow 85 
up and bacteriological cultures for enteric pathogens and virological screening for the 86 
presence of rotavirus and enteric adenoviruses was performed. A total of 41 children were 87 
included in the study along with a control group. A control group of children (established 88 
using the same criteria) free from infection of D. fragilis and confirmed by PCR (as described 89 
below), were included in the study. Where possible control subjects were age and sex 90 
matched with D. fragilis infected children. However, these were not possible for five 91 
children. In the majority of these cases (90%, 37/41) only a single stool sample was collected 92 
and analysed. 93 
 94 
Microbiological analysis 95 
Laboratory diagnosis was performed by microscopy of permanently stained fixed faecal 96 
smears and by real-time PCR as previously described (Stark et al. 2010a). Bacterial cultures 97 
were performed using standard microbiological techniques to rule out the following 98 
infections; Salmonella spp., Shigella spp., Campylobacter spp., Yersinia enterocolitica, 99 
Vibrio spp., Plesiomonas spp., Aeromonas and Clostridium difficile. Virology testing was 100 
performed by an immunochromatographic screening test (Adeno/Rota STAT-PAK; Chembio 101 
Diagnostic Systems Inc., Sydney) for the detection of adenovirus and rotavirus antigen in 102 





Statistical methods 105 
Differences between means of gastrointestinal symptoms of control subjects and D. fragilis 106 






A total of 41 children were identified from laboratory and hospital records as meeting the 110 
inclusion criteria for the study. All 41 children had laboratory confirmed D. fragilis infection 111 
along with clinical notes detailing symptoms, antimicrobial treatment regime and follow up 112 
stool samples to check for parasite clearance following treatment. The study group ranged in 113 
age from 1 to 15 years with 88% (n = 36) less than 10 years of age (Fig. 1). None of the 114 
children were immunosuppressed. No bacterial pathogens were isolated from the stools of the 115 
41 D. fragilis infected children. All children’s stools were also negative for enteric 116 
adenoviruses and rotaviruses. The control group comprised of 41 children, in which no D. 117 
fragilis was detected by microscopy and PCR. No bacterial or viral pathogens were detected 118 
in this group.  119 
 Initially, 47 D. fragilis infected children were identified from records; among them 120 
ten were infected with other enteric parasites; four with Blastocystis hominis, two with 121 
Cryptosporidium spp. and B. hominis, two with Endolimax nana, one with Entamoeba coli, 122 
and one with Enteromonas hominis. As Cryptosporidium spp. is considered pathogenic and 123 
B. hominis is potentially pathogenic and capable of causing gastrointestinal symptoms 124 
(Yakoob et al. 2010), these six children were excluded from the data dealing with symptoms 125 
and treatment. 126 
            Ninety-eight percent (40/41) of the children with D. fragilis infection presented with 127 
at least one or more gastrointestinal symptoms. Diarrhea (71%) was found to be the most 128 
common symptom followed by abdominal pain (29%) (Table 1). Persistent or chronic 129 
infection was reported in one child.  130 
 When compared to the control group diarrhea was significantly higher (P<0.002) in 131 




children. Originally, 44 control patients were identified, however three were removed 133 
because they harbored B. hominis and had symptoms of diarrhea. 134 
            A total of 41 children were treated with metronidazole and 35/41 (85%) reported 135 
complete resolution of symptoms. Follow up stool samples collected between 1-4 weeks 136 
following treatment were collected from these children and all showed clearance of the 137 
parasite. However in six children, gastrointestinal symptoms did not resolve following initial 138 
metronidazole treatment. Four of those children were subsequently treated with a repeat 139 
course of metronidazole for either 10 or 14 days and the other two children were treated with 140 
iodoquinol. Following this additional antimicrobial therapy the children reported improved 141 
clinical symptoms and follow up stool samples collected two weeks post treatment were 142 








This study, conducted over a 6 year period, highlights the association of D. fragilis with 148 
clinical signs of disease: 98% of the children infected with D. fragilis studied presented with 149 
gastrointestinal symptoms. Diarrhea was found in 29/41 (71%) of the children and abdominal 150 
pain in 12/41 (29%). The control group represents a group of symptomatic children free of D. 151 
fragilis infection. Diarrhea was, however, more common in children with D. fragilis infection 152 
compared to the control group. 153 
 There are other reports from various parts of the world that also describe an 154 
association between D. fragilis infection in children and various clinical symptoms, most 155 
commonly diarrhea and abdominal pain. A large study comprising of over 43,029 children 156 
first reported a correlation between D. fragilis infection and symptoms of diarrhea, abdominal 157 
pain and loose stools (Yang & Scholten, 1977). In that study, chronic infections were found 158 
in 2% of children. Spencer et al. (1983) reported a study from 104 children, in which diarrhea 159 
and abdominal pain were the most common symptoms in those with D. fragilis infection. 160 
Preiss et al. (1990) reported that among 102 children, seven had acute diarrhea, 39 had 161 
relapsing diarrhea, seven had bloody stools and 29 had abdominal pain. A retrospective study 162 
of 87 Swedish children diagnosed with D. fragilis found the majority of children had 163 
symptoms of diarrhea, abdominal pain and flatus (Norberg et al. 2003). Previous reports have 164 
also highlighted the propensity of the parasite to cause prolonged infection (Stark et al. 2005; 165 
Crotti & D'Annibale, 2007) with chronic infections reported in the literature to last as long as 166 
2 years (Wenrich, 1944). 167 
 Dientamoeba fragilis is a commonly encountered enteric protozoan parasite in 168 
children that should be considered in any differential diagnosis of gastrointestinal disease. 169 
Several studies have shown D. fragilis to be more prevalent than Giardia intestinalis in 170 




One serological study carried out in children reported a D. fragilis seroprevalence of 91% 172 
(Chan et al. 1996). When compared to the seroprevalence of Giardia and Cryptosporidium 173 
this study suggests childhood contact with Dientamoeba is common (Chan et al. 1996). Yang 174 
and Scholten (1977) found D. fragilis in 4.2% of individuals who submitted stools for 175 
parasitological examination during 1970-1974 in Ontario, Canada. Infections were found to 176 
be more common in children, with nearly half of the infections occurring in individuals under 177 
20 years old (Yang & Scholten, 1977). A recent study from the Netherlands found that D. 178 
fragilis infection was most common in children aged between 5-14 years (de Wit et al. 2001).  179 
Interestingly, an association was observed between D. fragilis infection and carriage of other 180 
enteric protozoa normally transmitted via the fecal-oral route. This association has been 181 
previously observed (Stark et al. 2010b) and suggests that transmission of D. fragilis also 182 
occurs in the same way (by the faecal oral route). There was no evidence for the presence of 183 
helminths in this study, which have previously been suggested to a host for D. fragilis (Stark 184 
et al. 2006). Recent studies also suggest that helminths such as Enterobius vermicularis 185 
appear to play no role in transmission of D. fragilis (Stark et al. 2010b, Barratt et al. 2011b).  186 
 Antimicrobial treatment most commonly used for treatment of D. fragilis infection in 187 
children includes metronidazole and idoquinol (diidohydroxyquin) (Stark et al. 2010b). 188 
Therapy with metronidazole was effective for most of the children in this study. Forty one 189 
children were administered the drug, with the duration of treatment varying from 5-10 days. 190 
85% of the children treated with metronidazole (35/41) resulted in the clearance of D. fragilis 191 
as determined by analyses of follow up stools and complete resolution of gastrointestinal 192 
symptoms. However 6/41 (15%) children who underwent metronidazole treatment failed to 193 
clear the infection parasitologically or clinically. There was no correlation between the dose 194 
received, the duration of treatment and treatment failure associated with metronidazole use. 195 




metronidazole for 2 weeks duration and the other two children were treated with iodoquinol. 197 
On follow up examination all children reported marked clinical improvement and clearance 198 
of parasite from stool samples. Iodoquinol has been widely used to treat D. fragilis infections 199 
(Butler, 1996). In a recent study, 27/33 children were successfully treated with clioquinol, a 200 
member of the same drug family as iodoquinol (Bosman et al. 2004).  201 
 There are varying reports of the efficacy of metronidazole treatment for D. fragilis 202 
infections in children. Spencer et al. (1979) reported that therapy with metronidazole was 203 
effective in 35 children (Spencer et al. 1979). Similarly, in New Zealand, metronidazole was 204 
successfully used in the treatment of dientamoebiasis in three children (Oxner et al. 1987). 205 
Preiss et al. (1990) studied 123 paediatric children with D. fragilis infections (Preiss et al. 206 
1990). They found metronidazole to be effective with 70% of children eliminating the 207 
parasite and symptoms after one treatment. A second treatment was required for 21 other 208 
children with another drug. Ten children were treated a third time in order to eliminate D. 209 
fragilis and accompanying abdominal complaints. They recommended a 10-day treatment 210 
with metronidazole for D. fragilis infections. Cuffari et al. (1998) showed that metronidazole 211 
was effective in treatment of five children (Cuffari et al. 1998). A study from Sweden 212 
included 32 children whom were treated with metronidazole. The drug was given at various 213 
doses for various lengths of time, and they found that only four children responded to the 214 
metronidazole treatment (Norberg et al. 2003). Recently it was also documented that two 215 
children presented with D. fragilis infection over prolonged periods (Stark et al. 2009). In 216 
that study, metronidazole was used initially, but subsequently treatment was done with 217 
paramomycin for 10 days to effect clearance of the parasite. At this point in time, it is not 218 
clear why some cases of dientamoebiasis do not respond to metronidazole treatment; such 219 
observations may be the result of metronidazole resistance or failure to comply with 220 




 In conclusion, this study serves to highlight the fact that children infected with D. 222 
fragilis typically have diarrhea. Studies such as those reported here, and elsewhere, strongly 223 
implicate D. fragilis as a common cause of gastrointestinal disease in children and other 224 
patient populations (Stark et al. 2006; Stark et al. 2010b; Barratt et al. 2011a). No D. fragilis 225 
was detected in the control group. We therefore recommend that all laboratories must 226 
routinely test for D. fragilis as treatment which eliminates the parasite usually results in the 227 
resolution of symptoms. It is essential a correct clinical and laboratory diagnosis is made so 228 
treatment can be initiated.  229 
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Table 1.  Summary of results from children with D. fragilis infection 350 
  





Age range 1-15 1-15 
Sex – male 





Female/male ratio 1/1.6 1/0.9 
Other enteric protozoa present 2/41 (5%) 1/41 (2%) 
Clinical signs shown by children   
Diarrhea 29/41 (71%) (P<0.002) 14/41 (34%) 
Abdominal pain/discomfort 12/41 (29%)  (NS) 9/41 (22%) 
Chronic diarrhea (>2 weeks) 1/41 (2%)  (NS) 0/41 (0%) 
Loose/abnormal stools 1/41 (2%)  (NS) 2/41 (5%) 
Vomiting 1/41(2%) (NS) 2/41(5%) 
Cramps/constipation 0/41(0%) 1/41(2%) 
Treatment   
Metronidazole 41/41  
Metronidazole treatment failures 6/41 (15%)  
 351 
 352 







LEGENDS TO FIGURE 357 
Figure 1. Age of children with dientamoebiasis, (M= Male; F=Female). 358 
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